论文部分内容阅读
目的:分析阿加曲班治疗后循环脑梗死的临床效果。方法:抽取2018年1月至2019年12月阳泉市第一人民医院收治的后循环脑梗死患者112例为研究对象，按随机数字表法将其分成研究组和对照组，每组56例。对照组给予常规治疗，研究组给予阿加曲班治疗，对两组患者治疗前后的美国国立卫生研究院卒中量表(NIHSS)评分、Barthel指数以及全血黏度切变率(高切)、全血相对切变率指数(高切)、血浆黏度、红细胞压积等血液流变学指标进行观察和比较。结果:治疗前，两组患者NIHSS评分、Barthel指数及血液流变学指标比较差异未见统计学意义(n P>0.05)；治疗后，两组NIHSS评分、Barthel指数及血液流变学指标均低于治疗前，且研究组低于对照组(n P0.05). After treatment, the NIHSS score, Barthel index and hemorheological indexes of the two groups were lower than those before treatment, and the above indexes in the study group were lower than those in the control group (n P<0.05).n Conclusions:Agatroban can effectively improve the degree of neurological deficits of patients, significantly alleviate hypercoagulable state, and improve the clinical comprehensive efficacy.